

## LIST OF TABLES

<b>Table 1</b>	Doses and Duration of Antiviral Drugs According to Viral Genotype	<b>58</b>
<b>Table 2</b>	Modification of Doses of Antiviral Drugs (from Product Labeling Except Where Noted)	<b>65</b>
<b>Table 3</b>	Treatment Milestones and Endpoints	<b>68</b>
<b>Table 4</b>	The patterns of virologic response in treating HCV infection.	<b>76</b>
<b>Table 5</b>	DAA's and HTA's in clinical development at the beginning of 2014	<b>80</b>
<b>Table 6</b>	Approved regimens of sofosbuvir	<b>82</b>
<b>Table 7</b>	Clinical trials of simprevir in genotype 1	<b>84</b>
<b>Table 8</b>	Approved regimens of simprevir in HCV genotype 1	<b>85</b>
<b>Table 9</b>	Direct acting antiviral drugs for HCV infection in clinical development	<b>89</b>
<b>Table10</b>	Therapeutic options likely to be available in 2014-2015.	<b>91</b>
<b>Table11</b>	The overall rates of sustained virologic response of the different currently approved HCV treatment regimens.	<b>92</b>

## LIST OF FIGURES

<b>Fig 1</b>	Simplified diagram of the structure of the Hepatitis C virus particle	<b>10</b>
<b>Fig 2</b>	Genome organisation of Hepatitis C virus	<b>11</b>
<b>Fig 3</b>	A simplified diagram of the HCV replication cycle	<b>17</b>
<b>Fig 4</b>	Hepatitis C infection in the United States by source	<b>28</b>
<b>Fig 5</b>	Serologic profile of Hepatitis C infection	<b>32</b>
<b>Fig 6</b>	Prevalence of hepatitis C worldwide in 1999	<b>39</b>
<b>Fig 7</b>	Outcomes of treatment regimens for chronic hepatitis C.	<b>51</b>
<b>Fig 8</b>	Virologic outcomes in patients with chronic HCV-4 receiving PEG-IFN- $\alpha$ plus ribavirin for 24, 36, or 48 weeks.	<b>71</b>